Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC

Eric J. Huselton, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Fax: (585) 273-1042

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



Dr. Eric Huselton received his medical degree from SUNY Downstate College of Medicine in 2012. He completed an Internal Medicine Residency Training Program and a Hematology/Oncology Fellowship at Washington University in Saint Louis/Bames Jewish Hospital in 2015 and 2018, respectively. Dr. Huselton is certified by the American Board of Internal Medicine.

Dr. Huselton is an Assistant Professor in the Division of Hematology and Oncology at the University of Rochester School of Medicine and Dentistry.

Dr. Huselton's special interests include allogenic hematopoietic cell transplant, haploidentical hematopoietic cell transplant, AML, MDS and hematologic malignancies. He aims to provide the best care by incorporating new treatments based on the most recent data, including clinical trials, targeted therapies, immunotherapy and cellular therapies. Dr. Huselton's hobbies include sailing, hiking and cooking.



  • Hematology - American Board of Internal Medicine
  • Internal Medicine - American Board of Internal Medicine
  • Medical Oncology - American Board of Internal Medicine


MD | SUNY Downstate College of Medicine

Post-doctoral Training & Residency

07/01/2015 - 06/30/2018
Fellowship in Hematology/Oncology at Washington University in St. Louis/Barnes Jewish Hospital

07/01/2013 - 06/30/2015
Residency in Internal Medicine at Barnes-Jewish Hospitals

06/01/2012 - 06/30/2013
Internship in Internal Medicine at Barnes-Jewish Hospitals

VIEW ALL expand_more


2019 - 2022
Wilmot Fellowship Award
Sponsor: Wilmot Cancer Institute
Location: Rochester, NY

Travel Award, Society of Hematologic Oncology

Harold A. Lyons Award for Excellence in Clinical Medicine

Alpha Omega Alpha
Location: SUNY Downstate College of Medicine

Downstate Alumni Summer Research Fellow

VIEW ALL expand_more

Clinical Trials

A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)

Lead Researcher: Eric J Huselton

This study will determine if the drugs olaprib and abiraterone are safe, well-tolerated and effective in treating metastatic castration-resistant prostate cancer. Metastatic castration-resistant prostate cancer is when the cancer has spread to parts of the body other than the prostate, and it is able to grow and spread even though drugs or other treatments to lower the amount of male sex hormones are being used to manage the cancer. Patients cannot have received prior chemotherapy or new hormonal agents metastatic castration-resistant prostate cancer. Approximately 720 patients globally will be randomized to treatment with either olaparib and abiraterone or placebo and abiraterone.

View Study Details

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Lead Researcher: Eric J Huselton

The investigators will prospectively determine whether the relapse-free and overall survival in patients who have cleared their leukemia-associated mutations treated with standard consolidation chemotherapy is superior to what is expected based on historical controls. The investigators will also prospectively determine the relapse-free and overall survival of patients who have not cleared their mutations. Because the relapse rate of patients with persistent mutations is expected to be high, treatment with either standard of care consolidation therapy alone or alloSCT will be permitted, at the discretion of the treating physician.

View Study Details


Journal Articles

Schroeder MA, Fiala MA, Huselton E, Cardone MH, Jaeger S, Jean SR, Shea K, Ghobadi A, Wildes T, Stockerl-Goldstein KE, Vij R. "A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2019 Apr 5; Epub 2019 Apr 05.

Huselton E, Slade M, Trinkaus KM, DiPersio JF, Westervelt P, Romee R. "Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2018 Oct 0; 24(10):2047-2055. Epub 2018 May 24.

Huselton E, Slade M, DiPersio JF, Westervelt P, Vij R, Uy GL, Fehniger TA, Abboud CN, Gao F, Schroeder MA, Romee R. "Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation." Bone marrow transplantation.. 2017 May 0; 52(5):769-771. Epub 2017 Jan 09.